Taiwanese Journal of Obstetrics & Gynecology (Oct 2016)

Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

  • Ming-Shyen Yen,
  • Jen-Ruei Chen,
  • Peng-Hui Wang,
  • Kuo-Chang Wen,
  • Yi-Jen Chen,
  • Heung-Tat Ng,
  • Yen-Hou Chang,
  • Yi Chang,
  • Hsiang-Tai Chao,
  • Kuan-Chong Chao,
  • Chi-Mu Chuang,
  • Chi-Hong Ho,
  • Huann-Cheng Horng,
  • Chen-Yu Huang,
  • Ling-Yu Jiang,
  • Chia-Hao Liu,
  • Hsin-Yang Li,
  • Pi-Lin Sun,
  • Hua-Hsi Wu,
  • Fong-Yuan Ju,
  • Chih-Ping Tsai,
  • Wen-Hsun Chang,
  • Yen-Mei Hsu,
  • Shu-Yun Huang,
  • Na-Rong Lee,
  • Chih-Yao Chen,
  • Wen-Chun Chang,
  • Chii-Hou Chen,
  • Ruey-Jian Chen,
  • Song-Nan Chow,
  • Yih-Ron Lien,
  • Bor-Ching Sheu,
  • Pao-Ling Torng,
  • Lin-Hung Wei,
  • Men-Luh Yen,
  • Wen-Ling Lee,
  • Kuan-Chin Wang,
  • Chih-Long Chang,
  • Chih-Ping Chen,
  • Tze-Chien Chen,
  • Jian-Pei Huang,
  • Ming-Chao Huang,
  • Yeou-Lih Wang,
  • Cheng-Chang Chang,
  • Jah-Yao Liu,
  • Her-Young Su,
  • Yu-Chi Wang,
  • Mu-Hsien Yu,
  • Ching-Chuang Chu,
  • Lee-Wen Huang,
  • Kok-Min Seow,
  • Tsung-Hsuan Lai,
  • Fa-Kung Lee,
  • Ching-Hui Chen,
  • Wei-Min Liu,
  • Jyh-Shin Chiou,
  • Ben-Shian Huang,
  • Yen-Feng Lu,
  • Sheng-Mou Hsiao,
  • Hsu-Dong Sun,
  • Wen-Yih Wu,
  • Sen-Wen Teng,
  • Kuo-Hu Chen,
  • Jeng-Hsiu Hung,
  • Hung-Cheng Lai,
  • Chiou-Chung Yuan,
  • Ching-Hung Hsieh,
  • Chin-Jung Wang,
  • Chia-Hao Chan,
  • Shing-Jyh Chang,
  • Chuan-Chi Shih,
  • Man-Jung Hung,
  • Shih-Tien Hsu,
  • Yu-Min Ke,
  • Chien-Hsing Lu,
  • Lou Sun,
  • Wei-Chun Chang,
  • Yao-Ching Hung,
  • Wu-Chou Lin,
  • Po-Hui Wang,
  • Tze-Ho Chen,
  • Meng-Hsing Wu,
  • Yiu-Tai Li,
  • Kuo-Feng Huang,
  • Fei-Chi Chuang,
  • Hung-Chun Fu,
  • Fu-Tsai Kung,
  • Kuan-Hui Huang,
  • San-Nung Chen,
  • An-Jen Chiang,
  • Ju-Yueh Li,
  • Wen-Shiung Liou,
  • Li-Te Lin,
  • Hsiao-Wen Tsai,
  • Kuan-Hao Tsui

DOI
https://doi.org/10.1016/j.tjog.2016.07.001
Journal volume & issue
Vol. 55, no. 5
pp. 625 – 634

Abstract

Read online

Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma. Currently, evidence from tumor biology found that these tumors showed alternation and/or mutation of genomes and the intracellular signal pathway. In addition, some preclinical studies showed promising results for targeting receptor tyrosine kinase signaling, phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway, various kinds of growth factor pathways, Wnt/beta-catenin signaling pathway, transforming growth factor β/bone morphogenetic protein signal pathway, aurora kinase A, MDM2 proto-oncogene, histone deacetylases, sex hormone receptors, certain types of oncoproteins, and/or loss of tumor suppressor genes. The current review is attempted to summarize the recurrent advance of targeted therapy for uterine sarcomas.

Keywords